HRMY Share Price Performance
US$28.79
-4.81 (-14.32%)
39.1% undervalued intrinsic discount
US$47.30
Fair Value
Price US$28.79
AnalystConsensusTarget US$47.30
AnalystLowTarget US$25.00
AnalystHighTarget US$61.87
Fair ValueUS$47.30
Share Pricen/a
Harmony Biosciences Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 176 Fair Values set on narratives written by author
HRMY Community Narratives
AN
Fair Value US$47.3 39.1% undervalued intrinsic discount
Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
1users have liked this narrative
0users have commented on this narrative
101users have followed this narrative
AN
Fair Value US$25 15.2% overvalued intrinsic discount
WAKIX Reliance Will Invite Patent Expiry And Pricing Woes
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$61.87 53.5% undervalued intrinsic discount
Aging Populations And WAKIX Trials Will Expand Rare Disease Treatment
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
WAKIX Reliance Will Invite Patent Expiry And Pricing Woes
Key Takeaways Over-reliance on a single key product exposes the company to concentration risk and vulnerability when patent protections expire or rivals enter the market. Evolving payer, regulatory, and scientific landscapes threaten pricing power, future earnings visibility, and long-term demand for the company's portfolio.Read more
55
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$25
15.2% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-4.77% p.a.
Profit Margin
11.57%
Future PE
20.81x
Price in 2029
US$30.55
Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
Key Takeaways Expanding addressable markets and a diversified pipeline position Harmony for sustained revenue growth with reduced dependence on any single product. Strong commercial execution and strategic capital management enable continued R&D investment, life cycle extension, and resilience against future competition.Read more
509
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
101users have followed this narrative
AN
US$47.3
39.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
16.17% p.a.
Profit Margin
27.33%
Future PE
9.49x
Price in 2029
US$57.79
Aging Populations And WAKIX Trials Will Expand Rare Disease Treatment
Key Takeaways Robust WAKIX growth and expansion into new indications position Harmony for sustained, outsized revenue and margin gains beyond market expectations. Strong cash reserves and business development set up Harmony as a leading consolidator and innovator in rare neurological diseases and regenerative therapies.Read more
101
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$61.87
53.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
20.88% p.a.
Profit Margin
28.74%
Future PE
10.47x
Price in 2029
US$75.55
Trending Discussion
Recently Updated Narratives
AN
HRMY: Earlier Generic Threat To Key Franchise Will Drive Share Repricing
Fair Value: US$25 15.2% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HRMY: Legal Overhang On Key Sleep Franchise Will Shape Future Upside
Fair Value: US$47.3 39.1% undervalued intrinsic discount
101 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HRMY: Raised Guidance And Product Pipeline Progress Will Support Bullish Upside Potential
Fair Value: US$61.87 53.5% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Harmony Biosciences Holdings, Inc. Key Details
About HRMY
- Founded
- 2017
- Employees
- 293
- CEO
- WebsiteView website
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
